Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 2.705
-4.95 %
$ 269 M
Market Cap
-5.27
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Aquestive Therapeutics, Inc.
| Revenue | 57.6 M |
| Cost Of Revenue | 17.9 M |
| Gross Profit | 39.7 M |
| Operating Expenses | 70.5 M |
| Operating Income | -30.8 M |
| Other Expenses | 13.4 M |
| Net Income | -44.1 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 57.6 | 50.6 | 47.7 | 50.8 | 45.8 | 52.6 | 67.4 | 66.9 | 51.8 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 17.9 | 20.8 | 19.4 | 15.0 | 13.0 | 20.4 | 21.0 | 19.8 | 16.4 |
| Gross Profit | 39.7 | 29.8 | 28.3 | 35.8 | 32.9 | 32.2 | 46.4 | 47.1 | 35.4 |
| OPERATING INCOME | |||||||||
| Operating Expenses | 70.5 | 44.9 | 70.4 | 70.5 | 75.8 | 84.9 | 95.4 | 47.2 | 36.3 |
| Selling, General and Administrative Expenses | 50.2 | 31.8 | 52.9 | 53.5 | 55.9 | 64.3 | 72.3 | 25.1 | 20.8 |
| Research and Development Expenses | 20.3 | 13.1 | 17.5 | 17.0 | 19.9 | 20.6 | 23.1 | 22.1 | 15.4 |
| Operating Income | (30.8) | (15.1) | (42.1) | (34.7) | (42.9) | (52.7) | (48.9) | (0.1) | (0.8) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 16.8 | 7.5 | 12.4 | 22.5 | 13.0 | 9.3 | 7.7 | 7.7 | 6.1 |
| Total Other Income | (13.4) | 7.5 | (12.3) | (35.9) | (12.9) | (13.6) | (12.4) | (8.8) | (8.8) |
| Pre-Tax Income | (44.2) | (7.6) | (54.4) | (70.5) | (55.8) | (66.2) | (61.4) | (8.9) | (9.6) |
| NET INCOME | |||||||||
| Tax Provision | 14 K | 0.2 | 5.8 | 19.5 | 9.6 | 6.4 | (4.7) | 7.7 | 6.0 |
| Net Income | (44.1) | (7.9) | (60.2) | (90.0) | (65.4) | (72.7) | (61.4) | (8.9) | (9.6) |
| EPS | 0.51 | 0.13 | 1.24 | 2.36 | 1.94 | 2.87 | 2.96 | 0.45 | 0.39 |